Earnings Releases·Nov 10, 2026, 5:06 PM ET

Cumberland Pharmaceuticals — Q3 2026 Earnings Summary

Net income for Q3 2026 reached $77.8 million, driven by an $81.1 million gain from the strategic transaction with Apotex Health, while continuing operations reported a net loss of $1.1 million compared to $2.7 million in the prior year; total revenue for the nine-month period rose to $2.5 million from $719,247 in the prior year.
The company executed a strategic pivot to a development-focused model following the July 1, 2026, closing of its transaction with Apotex Health, which generated $100 million in proceeds and allowed for the payment of $22.5 million in cash dividends and $5.2 million in line of credit repayments.
Cumberland plans to submit a New Drug Application (NDA) for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD) utilizing a rolling review and Phase 2 FIGHT DMD data, with the FDA having granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations for this indication.
Financial strength has improved significantly with cash and cash equivalents increasing to $80.6 million and shareholders' equity rising to $72.5 million as of September 30, 2026, though operating and investing cash flows remained negative for the nine-month period.